Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders

Suggested Citation

Dysoley L., Cassidy-Seyoum S., Adhikari B., Dahal A., Phoumen N., Srey S., Phalla T., Vonn P., Engrkruy B., Sovanarath O., Mengkea H., Rathana P., Makara I., Heng P.K., Heng Y., Khlok H., Pong K., Moeng T., Vantha S., Soviet U., Ravuth R., Bunreth V., Vannak K., Sokhann M., Kimmen K., Dy K., Samol S., Lo K., Sokunthea N., Kry H., Kanha L., Naren L., Oum S., Sovann Y., Channavuth R., Bunmeng C., Hughes J., Brindle H., Hu Y., Peng S., Mardi P., Chanry I., Preap S., Heoy S., Sabawoon F., Sokha T., Ringwald P., Lynch C.A., Price R.N., Tripura R., von Seidlein L., Devine A., Thriemer K. Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders. Malaria Journal Vol.25 No.1 (2026). doi:10.1186/s12936-025-05691-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114715

Availability

Collections